Historical Medical Device Changes from NMPA (CFDA) Announced Today

CFDA Cracking Down on Labeling—36% Defects Have Labelling Issues
June 25, 2018
Illustration of a laptop computer showing Grace Fu Palma speaking during a presentation for a webinar
Grace Palma, CEO of China Med Device, is interviewed by RAPS on China Medical Device Amendment
June 27, 2018
0

Historical Medical Device Changes from NMPA (CFDA) Announced Today

Categories
Tags

The last time the NMPA (CFDA) “Medical Device Supervision and Management Regulations” were completely overhauled was in 2014 with a supplemental update in 2017. Today (June 25th, 2018) the new draft regulations are going through historical changes focusing on expediting innovation and achieving much needed reform.  It is timely in that U.S. tariffs are anticipated to be levied at 25% duty on many of the medical devices shipped from China to the U.S.

Articles impacted: 12 articles newly added, 2 deleted and 39 modified.

Major changes:

  1. Perfecting medical device registration holder system. The registration holder can now be independent of the manufacturer.
  2. Relaxed the requirements for CER and clinical trials and acceptance of overseas clinical trial data. Streamline Innovation Approval and Priority Review to expedite certain devices entry.
  3. Exempted the requirement of home-country-approval for imported devices.
  4. Class II domestic devices approval has been moved from provincial SDA (CFDA) to the national one. Provincial and local SDA (CFDA) will establish career inspectors like the regional FDA inspectors in the U.S.
  5. Type testing and 3rd party reviews are being encouraged.

 

Please email info@ChinaMedDevice.com if you would like to schedule a consultation about these transformational changes from the NMPA (CFDA).

 

About China Med Device, LLC

China Med Device, LLC (https://ChinaMedDevice.com) provides turn-key solutions for western medical device/IVD companies to enter China with regulation and commercialization services. Our CFDA regulatory services cover strategy, RA, clinical evaluation, CRO, QA and post market compliance. We are experienced in handling innovation approvals and priority reviews. Our commercial services cover market assessment research, reimbursement, partnership, distribution qualification and management. We have offices in Beijing, Suzhou and Boston. Our management team has 100+ years of combined experience in medical device and IVD and has been involved with 1,000+ CFDA certificates and 250+ companies’ success.

 

 

Related posts:

  1. CFDA announced the new “Medical Device Classification Catalogue”! On August 31, CFDA announced the new “Medical Device Classification Catalogue”. This new catalogue will be implemented on August 1ST, 2018. The revised medical device classification directory has significant implications for medical...
  2. Beijing Provincial CFDA Announced a Notice of “Strengthen the Supervision and Inspection of Import Medical Device Distributors” On September 11th, 2017, Beijing provincial CFDA announced a notice of “Strengthen the Supervision and Inspection of Import Medical Device Distributors”. 1.      Objectives: ·       Understand the operation quality control status...
  3. China 1.2 Billion registered cell phone users: CFDA Mobile Medical Device Technical Review Guideline Announced CFDA is regulating mobile medical devices even closer. On 29 Dec, 2017, Guideline for Technical Review of Mobile Medical Device Registration issued by CFDA, specifying the data preparing for registration...
  4. China Announced The World’s Second Largest Medical Device Market According to the statistics of China Medical Device Industry Association, in 2016, the annual output value of China’s medical device industry reached 276.5 billion yuan, an increase of 13% over...